India, Aug. 17 -- argenx SE (ARGX) shares surged 16 on Monday's trading after the company reported positive topline results from its Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis.
The stock is currently trading at $988.46, up $137.17 or 16.11%, on the Nasdaq. It opened at $927.33 after closing the previous session at $851.29. The stock has traded between $650.01 and $1,002.16 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....